Our drug target MR studies have identified a direct correlation between the risk of epilepsy and HMGCR, encompassing all types (OR = 1.17, 95% CI = 1.03–1.32, p = 0.01), focal epilepsy (OR = 1.24, 95% CI = 1.08–1.43, p = 0.003), and focal epilepsy characterized by documented lesions other than hippocampal sclerosis (OR = 1.05, 95% CI = 1.01–1.10, p = 0.02). Here, HMGCR is linked to epilepsy.